MCRB News and Press, Seres Therapeutics Inc. From 09/11/23

2023-09-11 03:47:28 ET Summary Seres Therapeutics launched VOWST for recurrent C. difficile infection in early June, in partnership with Nestle Health. VOWST represents a significant improvement over current standard of care. Considering high efficacy, safety and ease-of administr...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 12:15 p.m. ET. An audio webcast of the presentation wil...

2023-09-01 14:03:22 ET Summary Seres Therapeutics trades near its 52-week low and presents an asymmetric risk-reward profile. The company's lead asset, SER-109, has successfully concluded its Phase III clinical trial for recurrent Clostridioides difficile infection. Seres Ther...

Invaio achieves first registration for citrus greening solution featuring Trecise™ technology PR Newswire FDACS approves first registration of Invaio's Trecise™ technology to deliver ArborBiotic™ for the suppression of citrus greening in oranges Citrus...

2023-08-08 15:03:09 ET Seres Therapeutics, Inc. (MCRB) Q2 2023 Earnings Conference Call August 08, 2023, 08:30 AM ET Company Participants Carlo Tanzi - IR Officer Eric Shaff - President and CEO Lisa von Moltke - EVP and Chief Medical Officer Terri Young - Chi...

2023-08-08 07:11:21 ET Seres Therapeutics press release ( NASDAQ: MCRB ): Q2 GAAP EPS of $0.36 misses by $0.17 . Revenue of $126.47M (+10266.4% Y/Y) beats by $0.8M . For further details see: Seres Therapeutics GAAP EPS of $0.36 misses by $0.17, revenue of...

– VOWST TM is the first orally administered microbiome therapeutic FDA-approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI (rCDI) – – VOWST early commercial uptake encouraging with strong in...

2023-08-07 15:44:27 ET Seres Therapeutics ( NASDAQ: MCRB ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is $0.55 and the consensus Revenue Estimate is $125.67M. Over the last 1 year, MCRB has beat...

2023-08-03 15:37:39 ET Summary Seres and Nestlé launched the first oral drug to prevent recurrence of Clostridioides difficile infection (CDI). CDI treatment wrings high costs from the healthcare system and individual patients, ensuring broad insurance coverage in the next fe...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 8, 2023 at 8:30 a.m. ET to discuss second quarter results and provide a general business update. To access the con...